Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer
Status:
Terminated
Trial end date:
2011-10-06
Target enrollment:
Participant gender:
Summary
This phase II trial evaluated the impact of Oxaliplatin and Gemcitabine in patients with
recurrent or advanced transitional cell carcinoma of the bladder. The combination of
Oxaliplatin and Gemcitabine is considered investigational and this study will help in
determining if their activity and toxicity profiles are comparable or better than the
standard regimens.